RAYMOND JAMES FINANCIAL INC
Position in LNTH — Lantheus Holdings, Inc.
CIK 720005
ST. PETERSBURG, FL
Position in LNTH
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$7,059,888
-$198,454 QoQ
Shares Held
93,077
-14.7% QoQ
Ownership
0.143%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 1.2699163058542926.ToString("F0")%
Shared 0.ToString("F0")%
None 98.7300836941457.ToString("F0")%
Common Shares in LNTH Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026RAYMOND JAMES FINANCIAL INC holds $784,401,544 across 37 Drug Manufacturers - Specialty & Generic names. LNTH ranks #12 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
3,166,615 | $374,325,557 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
601,487 | $79,239,894 | |
| 3 | HLN |
Haleon plc
|
6,264,041 | $62,703,048 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,816,715 | $54,719,453 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
1,898,337 | $45,427,201 | |
| 6 | PBH |
Prestige Consumer Healthcare Inc.
|
556,460 | $32,981,383 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
47,576 | $28,211,615 | |
| 8 | VTRS |
Viatris Inc
|
1,855,553 | $25,068,518 |
All Filings in LNTH
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,059,888 | 93,077 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $7,258,342 | 109,066 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $5,814,593 | 113,367 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $38,529,698 | 470,678 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $36,733,319 | 376,366 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $36,183,078 | 404,461 | Shares | Defined | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||